Superior Efficacy and Safety of Osimertinib in Untreated EGFR-Mutated Advanced NSCLC
The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; […]
Superior Efficacy and Safety of Osimertinib in Untreated EGFR-Mutated Advanced NSCLC Read More »
